智通财经APP讯,德琪医药-B(06996)发布公告,本公司董事会欣然宣布,集团自主研发的ATG-201(一种用于治疗B细胞相关自身免疫性疾病的CD19/CD3双特异性T细胞衔接抗体)的I期ATTRACT研究,已获得澳大利亚人类研究伦理委员会(HREC)批准,并已完成向治疗用品管理局(TGA)提交临床试验通知(CTN)的程序。
智通财经APP讯,德琪医药-B(06996)发布公告,本公司董事会欣然宣布,集团自主研发的ATG-201(一种用于治疗B细胞相关自身免疫性疾病的CD19/CD3双特异性T细胞衔接抗体)的I期ATTRACT研究,已获得澳大利亚人类研究伦理委员会(HREC)批准,并已完成向治疗用品管理局(TGA)提交临床试验通知(CTN)的程序。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.